Login to Your Account

Clinic Roundup

Friday, April 29, 2011
Otonomy Inc., of San Diego, reported positive data from a Phase Ib study of the company's lead product candidate, OTO-104, in patients with Ménière's disease. Study results showed OTO-104 to be well-tolerated at both doses tested when delivered via a single intratympanic injection. Additionally, while not powered to demonstrate statistically significant clinical activity, data from the trial showed that patients receiving OTO-104 experienced greater reductions in vertigo frequency and tinnitus compared to patients receiving placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription